A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Grisofulvin

Tubulin Inhibiting Agent class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2017-03-06
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$0.266/unit
1 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.266
Across all dosage forms in distribution.
Highest NADAC
$0.266
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema7 entries indexed · 4 visible
What is Grisofulvin used for?

Grisofulvin is a Tubulin Inhibiting Agent medication tracked in Medicare Part D.

Is there a generic for Grisofulvin?

No. Grisofulvin is brand-only with no generic equivalents currently in market.

How much does my plan pay for Grisofulvin?

Across 329 Part D plans, Grisofulvin averages $0.266/unit (NADAC). Lowest available: $0.266/unit. Highest in distribution: $0.266/unit.

Is Grisofulvin on the FDA shortage list?

No. Grisofulvin is not currently on the FDA Drug Shortage Database.

3 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Tubulin Inhibiting Agent4 alternatives in D1
01
Griseofulvin
Brand: Ultramicrosize Griseofulvin
$0.266Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
02
Griseofulvin (Microsize)
Brand: Griseofulvin
$0.266Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Ultramicrosize Griseofulvin
Brand: Fulvicin P/G 165
$2.87Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
04
Ultramicrosize Griseofulvin Tablets
Brand: Ultramicrosize Griseofulvin
$2.87Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (1 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.